If you would like to continue working on the submission, click on the "Edit" tab at the top of the window.
If you have not resolved the issues listed above, your draft will be declined again and potentially deleted.
If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors.
Please do not remove reviewer comments or this notice until the submission is accepted.
Where to get help
If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews.
If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the
talk page of a
relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed.
To improve your odds of a faster review, tag your draft with relevant
WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags.
Please note that if the issues are not fixed, the draft will be declined again.
Comment: As noted by previous reviewer, currently the biomedical claims here are supported by articles from news media instead of medical professionals, which is to be avoided under
WP:MEDRS. Please make sure to include medical research from reliable and independent institutions to back up those claims.
Tutwakhamoe (
talk) 21:34, 18 July 2023 (UTC)
Comment: Per
WP:NCCORP, 'Inc.' etc. should not be used in the article title, if this is accepted. IMO, there is little if any reason why Synchron should redirect to Beckman Coulter (it isn't even covered in that article). Therefore, I would suggest deleting the existing redir and placing this article at Synchron instead.
DoubleGrazing (
talk) 12:55, 17 July 2023 (UTC)
Comment: Given how
Synchron currently redirects to
Beckman Coulter, the name of the article should be changed to
Synchron Inc. (or however the company referrs) upon publishing, and a disambiguation page
Synchron (disambiguation) would need to be created as well.
Tutwakhamoe (
talk) 20:29, 12 July 2023 (UTC)
Comment: Make sure that the sourcing in the article meets
WP:MEDRS standard on biomedical claims.
Catalk to me! 04:03, 9 July 2023 (UTC)
Synchron's first product is the
Stentrode Motor Neuroprosthesis.[5] The company announced in September 2019 that the first patient was implanted with the Stentrode Motor Neuroprosthesis in Melbourne, Australia.[6] In 2021, Synchron received
FDA approval to conduct early feasibility studies and begin
human trials in the United States.[7][8] They are the first company to have ever received such FDA approval, granting them the legal rights to conduct BCI trials in human patients.[9] In July 2022, Synchron began enrolling patients in its first U.S. clinical trial.[citation needed]
The company plans to apply for full FDA approval following clinical trials, and will seek to make the device more affordable to the public by applying for
Medicare coverage in the United States. According to Wired, Synchron CEO Thomas Oxley has said that the cost of the implant may be "in the order of magnitude of the cost of a car".[14]
Technology
The Stentrode
neurovascular implant is inserted into a
blood vessel near the
motor cortex of the brain, with a minimally-invasive procedure via the
jugular vein.[15] The 8
mm thick Stentrode is composed of a tubular
nitinol mesh,[7] contains 16 electrodes for recording aggregate neuronal activity,[16] and is connected by a fine wire under the skin to a coin-sized implant in the chest — this transmitter unit (called the Synchron Switch) decodes the signals from the motor cortex using machine learning algorithms, and enables
bluetooth communication with other devices.[4][17][18] Based on preliminary human trials, it is capable of sending 20 characters per minute.[17]